ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in RIGL — Rigel Pharmaceuticals Inc
CIK 1164508
BOSTON, MA
Position in RIGL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$4,524,927
-$13,192,087 QoQ
Shares Held
167,342
-59.5% QoQ
Ownership
0.896%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RIGL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $2,519,535,758 across 72 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
738,378 | $366,774,503 | |
| 2 | INCY |
Incyte Corp
|
2,744,958 | $311,168,438 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
393,685 | $245,478,344 | |
| 4 | EXEL |
Exelixis, Inc.
|
4,365,926 | $237,550,033 | |
| 5 | GMAB |
Genmab A/S
|
4,975,324 | $136,672,150 | |
| 6 | RPRX |
Royalty Pharma plc
|
2,435,341 | $136,549,569 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
1,704,623 | $133,420,842 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
249,758 | $71,173,537 |
All Filings in RIGL
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4,524,927 | 167,342 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $17,717,014 | 413,659 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $5,278,615 | 186,326 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $411,741 | 21,983 | Shares | Defined | 2025-08-13 | |
| 2021-09-30 | $498,722 | 137,389 | Shares | Defined | 2021-11-12 | |
| 2020-12-31 | $4,411,942 | 1,260,555 | Shares | Defined | 2021-02-12 | |
| 2020-09-30 | $4,033,972 | 1,680,822 | Shares | Defined | 2020-11-12 | |
| 2020-06-30 | $2,022,603 | 1,105,248 | Shares | Defined | 2020-08-12 | |
| No filing history on record for this holder in this stock. | ||||||